Addex and SIB receive Innosuisse grant to repurpose potent dopamine antagonist

Addex Therapeutics and SIB have been awarded a CHF600K Innosuisse grant to apply computational approaches developed by SIB to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist. Dopamine is a major neurotransmitter in the central nervous system and D1 receptors are believed to play an important role in the control of diverse aspects of brain function, including cognition, motivation, motricity, sleep, and memory.

“The diversity of D1-dopaminergic systems in the body and availability of promising clinical and pre-clinical study data is a strong basis to successfully apply advanced computational approaches, such as those developed by SIB, to identify new therapeutic opportunities for ADX10061,” said Robert Lütjens, PhD, Head of Discovery Biology at Addex, a clinical-stage pharmaceutical company headquartered in Geneva and pioneering allosteric modulation-based drug discovery and development. “We believe SIB’s innovative approaches, including artificial intelligence, deep learning techniques and molecular modelling have the potential to generate testable hypotheses for new therapeutic effects of ADX10061.”

“The Addex molecule, ADX10061, provides a perfect opportunity to deploy the advanced computational technologies developed at the SIB to explore further its biological properties and discover additional potential therapeutic indications,” said Christine Durinx, PhD, SIB Executive Director. “Our multidisciplinary team of data scientists are excited to have the opportunity to work with Addex on this Innosuisse funded project.”

“This Innosuisse funded SIB collaboration is another example of our strategy to access technologies through collaborative approaches to advance our portfolio for the benefit of both patients and shareholders,” said Tim Dyer, CEO of Addex. “We are honoured to have the opportunity to work with the SIB team and believe they have the skills and expertise to identify new potential therapeutic opportunities for ADX10061.”

https://www.sib.swiss/about-sib/news/10751-addex-and-sib-receive-innosuisse-grant-to-repurpose-potent-dopamine-antagonist